Harmony Biosciences Holdings Inc [HRMY] stock prices are up 3.60% to $34.81 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HRMY shares have gain 0.12% over the last week, with a monthly amount drifted -6.63%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, UBS started tracking the stock with Buy rating on September 10, 2024, and set its price target to $56. On June 21, 2024, Citigroup initiated with a Buy rating and assigned a price target of $48 on the stock. BofA Securities downgraded its rating to a Underperform but stick to its price target of $30 on January 02, 2024. Goldman downgraded its rating to a Sell and reduced its price target to $31 on September 25, 2023. Berenberg started tracking with a Buy rating for this stock on September 07, 2023, and assigned it a price target of $59. In a note dated April 20, 2023, BofA Securities initiated an Neutral rating and provided a target price of $35 on this stock.
The stock price of Harmony Biosciences Holdings Inc [HRMY] has been fluctuating between $18.61 and $40.60 over the past year. Currently, Wall Street analysts expect the stock to reach $52.33 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $34.81 at the most recent close of the market. An investor can expect a potential return of 50.33% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
The Harmony Biosciences Holdings Inc [NASDAQ:HRMY] reported sales of 656.11M for trailing twelve months, representing a surge of 28.76%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.23 and Total Capital is 0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.90 points at the first support level, and at 32.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.43, and for the 2nd resistance point, it is at 36.04.
Ratios To Look Out For
It’s worth pointing out that Harmony Biosciences Holdings Inc [NASDAQ:HRMY]’s Current Ratio is 3.13. In addition, the Quick Ratio stands at 3.09 and the Cash Ratio stands at 2.16. Considering the valuation of this stock, the price to sales ratio is 3.02, the price to book ratio is 3.67 and price to earnings (TTM) ratio is 17.82.
Transactions by insiders
Recent insider trading involved JEFFREY G DIERKS, Officer, that happened on Oct 03 ’24 when 14961.0 shares were purchased. CHIEF COMMERCIAL OFFICER, Dierks Jeffrey completed a deal on Oct 01 ’24 to sell 400.0 shares. Meanwhile, Officer JEFFREY G DIERKS bought 21796.0 shares on Oct 01 ’24.
